{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T00:04:54Z","timestamp":1761609894864},"reference-count":35,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2012,6,1]],"date-time":"2012-06-01T00:00:00Z","timestamp":1338508800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2012,6]]},"DOI":"10.1016\/j.autrev.2011.10.012","type":"journal-article","created":{"date-parts":[[2011,10,27]],"date-time":"2011-10-27T11:34:47Z","timestamp":1319715287000},"page":"558-562","source":"Crossref","is-referenced-by-count":13,"title":["To switch or not to switch after a poor response to a TNF\u03b1 blocker? It is not only a matter of ACR20 OR ACR50"],"prefix":"10.1016","volume":"11","author":[{"given":"Maya H.","family":"Buch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Rubbert-Roth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianfranco","family":"Ferraccioli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.autrev.2011.10.012_bb0005","doi-asserted-by":"crossref","first-page":"R163","DOI":"10.1186\/ar2848","article-title":"ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature","volume":"11","author":"Alivernini","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2011.10.012_bb0010","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/ard.2010.137174","article-title":"Study of the common genetic background for rheumatoid arthritis and systemic lupus erythematosus","volume":"70","author":"Orozco","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.10.012_bb0015","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s11926-009-0050-0","article-title":"Rheumatoid arthritis genetics: 2009 update","volume":"11","author":"Plenge","year":"2009","journal-title":"Curr Rheumatol Rep"},{"issue":"Suppl 1","key":"10.1016\/j.autrev.2011.10.012_bb0020","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1007\/s11739-011-0668-6","article-title":"Pathogenetic, clinical and pharmaco-economic assessments in Rheumatoid Arthritis (RA)","volume":"6","author":"Ferraccioli","year":"2011","journal-title":"Internal Emerg Med"},{"key":"10.1016\/j.autrev.2011.10.012_bb0025","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1093\/rheumatology\/kep155","article-title":"A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis","volume":"48","author":"Vastesaeger","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.autrev.2011.10.012_bb0030","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1136\/ard.2009.121160","article-title":"A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study","volume":"69","author":"Visser","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.10.012_bb0035","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1136\/ard.2007.084715","article-title":"Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis","volume":"68","author":"Potter","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.10.012_bb0040","first-page":"1670","article-title":"Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study","volume":"34","author":"Mancarella","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2011.10.012_bb0045","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0140-6736(01)06075-5","article-title":"Rheumatoid arthritis","volume":"358","author":"Lee","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2011.10.012_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta10420","article-title":"A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness","volume":"10","author":"Chen","year":"2006","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.autrev.2011.10.012_bb0055","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1136\/ard.2003.009589","article-title":"Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense","volume":"62","author":"van Vollenhoven","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.10.012_bb0060","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/art.22617","article-title":"Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept","volume":"57","author":"Buch","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.10.012_bb0065","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1136\/ard.2006.054742","article-title":"Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?","volume":"66","author":"Hjardem","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.10.012_bb0070","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/ard.2006.068304","article-title":"Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study","volume":"66","author":"Furst","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.10.012_bb0075","first-page":"26","article-title":"Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial","volume":"26","author":"Smolen","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2011.10.012_bb0080","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.22331","article-title":"Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study","volume":"56","author":"Hyrich","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.10.012_bb0085","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar1881","article-title":"Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period","volume":"8","author":"Gomez-Reino","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2011.10.012_bb0090","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2011.10.012_bb0095","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2011.10.012_bb0100","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.10.012_bb0105","doi-asserted-by":"crossref","DOI":"10.1136\/ard.2009.119222","article-title":"Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate","author":"Cohen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.10.012_bb0110","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/ard.2008.105064","article-title":"Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent?","volume":"69","author":"Finckh","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.10.012_bb0115","first-page":"68","article-title":"Predictive factors of response to rituximab in rheumatoid arthritis with inadequate response or intolerance to anti-TNF: data from the SMART trial","volume":"68","author":"Sellam","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.10.012_bb0120","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1136\/ard.2009.126532","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs","volume":"69","author":"Smolen","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.10.012_bb0125","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1136\/ard.2007.069872","article-title":"Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue","volume":"66","author":"Van Vollenhoven","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.10.012_bb0130","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/ard.2006.068304","article-title":"Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the OPPOSITE study","volume":"66","author":"Furst","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.10.012_bb0135","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar1881","article-title":"BIOBADASER Group. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period","volume":"8","author":"Gomez-Reino","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2011.10.012_bb0140","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa050524","article-title":"Abatacept for rheumatoid arthritis refractory to tumour necrosis factor alpha inhibition","volume":"353","author":"Genovese","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2011.10.012_bb0145","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1136\/ard.2008.092932","article-title":"IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24 week multicentre randomised placebo-controlled trial","volume":"67","author":"Emery","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2011.10.012_bb0150","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1136\/ard.2010.148759","article-title":"Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries","volume":"70","author":"Chatzidionysiou","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.autrev.2011.10.012_bb0155","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.10302","article-title":"The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial","volume":"46","author":"St Clair","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.autrev.2011.10.012_bb0160","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/ard.2008.092833","article-title":"Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis","volume":"68","author":"Radstake","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.autrev.2011.10.012_bb0165","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the longterm efficacy of infliximab in Crohn's disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.autrev.2011.10.012_bb0170","first-page":"96","article-title":"Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and metaanalysis","volume":"29","author":"Remy","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.autrev.2011.10.012_bb0175","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1136\/ard.2009.126573","article-title":"Current evidence fort he management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the managment of rheumatoid arthritis","volume":"69","author":"Nam","year":"2010","journal-title":"Ann Rheum Dis"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997211002321?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997211002321?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T17:25:44Z","timestamp":1560878744000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997211002321"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2012,6]]}},"alternative-id":["S1568997211002321"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2011.10.012","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2012,6]]}}}